Global Placental Stem Cell Therapy for Neurological Disorders Market Research Report | Segmented by Type (Allogeneic Placental Stem Cell Therapy, Autologous Placental Stem Cell Therapy), By End-User (Hospitals & Specialty Clinics, Clinics Research Organizations, Research Institutes & Academics); and Region- Size, Share, Growth Analysis | Forecast (2024 2030)

Market Size and Overview:

The Global Placental Stem Cell Therapy for Neurological Disorders Market was valued at USD 464.96 Million and is projected to reach a market size of USD 1.8 Million by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 21.4%.

Placental stem cells are derived from the bodily fluids of newborn infants, including placental blood. Both placental blood and tissues contain abundant perinatal stem cells, with cord blood stem cells and umbilical cord tissues forming integral components of the placenta. The application of stem cell therapy has garnered acclaim for its significant contributions to innovative advancements in cancer management and healthcare. Conditions such as cancer, vascular disorders, and neurological disorders benefit from effective therapeutic solutions provided by placental stem cells. Stem cell therapy has recently emerged as a promising contender in gene therapy, showcasing potential for tissue repair and regeneration. The industry increasingly acknowledges the medicinal potential of stem cells for managing diseases and disorders.

The positive impact of the human placenta on the immune system is evident, and therapeutic applications of placental components, including amniotic membranes, contribute to wound healing, burn treatment, and oral cavity restoration. This fosters the expansion of the placental stem cell therapy market. While extensive research has mitigated risks associated with the derivation and cultivation of Placental Stem Cells (PSCs), ethical considerations persist. The development of induced pluripotent stem cells serves as a means to address these concerns. The growth of the placental stem cell therapy industry is propelled by the increasing volume of scientific investigations focusing on the therapeutic efficacy of placental stem cells for neurological disorder treatment and the establishment of stem cell line banking.

Key Market Insights:

In their pursuit of broadening the clinical uses of placental stem cell therapies, industry players actively embrace various technologies and methodologies. They focus on maintaining a steady standard of stem cell quality, emphasizing advancements in biobanking technologies. The promise of allogeneic human amniotic epithelial cells (hAECs) is demonstrated in addressing conditions like leukemia and bronchopulmonary dysplasia (BPD) through multiple stages of clinical trials. The increasing prevalence of allogeneic stem cell transplantation procedures positively impacts the sales outlook in the placental stem cell therapy market.

Ongoing developments in cell-based treatments increase interest in utilizing placental stem cell therapy for various illnesses, propelling the potential for increased sales. Notably, therapeutic effectiveness is observed in cell therapy products based on mesenchymal stem/stromal cells (MSCs), especially in the context of neurological disorders.

Global Placental Stem Cell Therapy for Neurological Disorders Market Drivers:

The growth of Global Placental Stem Cell Therapy is fueled by advancements in the scientific, technological, and medical fields. Recent swift advancements in the genetic engineering of human pluripotent stem cells (hPSCs) facilitate improvements in targeted differentiation, cell monitoring, gene function assessment, and genetic rectification. The emergence of nucleases-based technologies, including ZFNs, TALENs, and CRISPR/Cas9, has the potential to streamline genetic alterations in hPSCs and subsequent generations, owing to their elevated success rates and simplified design procedures.

Increasing funding for stem cell research contributes to enhancing market growth. The need for improved treatments for auto-immune conditions, neurological problems, and heart diseases drives increased investment in researching and developing these treatments. The prevalence of neurological disorders and other chronic illnesses further augments the market for placental stem cell therapy. The rise in chronic conditions worldwide necessitates effective treatments, with mesenchymal stem cells proving to be versatile in addressing a wide range of organ-related diseases and conditions. Stem cells' use in managing inflammation, immune system issues, and tissue breakdown continues to be a promising and effective approach.

Global Placental Stem Cell Therapy for Neurological Disorders Market Challenges:

The cell treatment market's expansion encounters hurdles attributed to its elevated costs. Despite the rising popularity of cell treatments as individuals explore the latest therapeutic options, their affordability remains a significant challenge. Basic joint injections, for instance, may incur costs of approximately $1,000, while more intricate procedures could escalate to around $100,000. Moreover, the stringent regulatory environment compounds the challenges faced by the market.

Although substantial progress has been made in pluripotent stem cell (PSC) research in the past three decades, a complete understanding of these cells for therapeutic purposes is yet to be achieved. The fundamental principles of generating, characterizing, and cultivating PSCs are widely acknowledged. While research has addressed many risks and issues associated with PSC creation and cultivation, ethical concerns persist. The development of induced pluripotent stem cells (iPSCs) plays a crucial role in addressing these ethical considerations.

Global Placental Stem Cell Therapy for Neurological Disorders Market Opportunities:

The placental stem cell market is positioned for substantial growth, offering a spectrum of promising opportunities. Placental stem cells exhibit notable versatility and effectiveness in treating neurological disorders. With ongoing research revealing new therapeutic possibilities, the market stands to benefit from the escalating demand for innovative and efficient treatments. The increasing awareness and acceptance of regenerative medicine contribute to a growing demand for alternative treatment options. The placental stem cell market holds abundant opportunities propelled by the expansion of clinical applications, technological advancements, collaborative initiatives, and rising patient demand. As continuous research and innovation pave the way forward, the market is poised to present lucrative business prospects in the forthcoming years.

Impact of COVID-19 on the Global Placental Stem Cell Therapy for Neurological Disorders Market:

The global outbreak of COVID-19 introduced a series of challenges that affected both the demand and supply aspects of the specialized therapeutic area. The pandemic disrupted clinical trials, crucial for advancing and validating new therapies, due to lockdowns, travel restrictions, and limited access to medical facilities. Despite these challenges, the pandemic highlighted the potential benefits of stem cell therapies, especially those derived from placental sources. Research into the immunomodulatory and anti-inflammatory properties of placental stem cells gained attention for treating COVID-19 complications. The overall impact of COVID-19 on the Placental Stem Cell market was moderate, and the market is poised for a significant resurgence with various opportunities.

Latest Trends/Developments:

Industry participants are demonstrating a strong inclination towards integrating advanced technologies and methodologies to maintain a consistent level of stem cell quality. This strategic approach aims to broaden the scope of clinical applications for placental stem cell therapies.

Within the placental stem cell therapy sector, enterprises are focusing on achieving a reliable and high-quality cell production process. Notably, ReNeuron, a key player in developing therapeutics derived from stem cells specific to the retina, is intensifying efforts to harmonize scientific precision with artistic precision. This approach ensures unwavering uniformity in cell manufacturing, a critical aspect for effectively addressing conditions like retinitis pigmentosa.

The placental stem cell therapy market is witnessing a growing interest in utilizing allogeneic stem cell transplantation as a comprehensive approach to treating neurological disorders. The field of cell therapy for neurological conditions is rapidly advancing. Notably, during the evaluation of various cell types, each demonstrates distinct benefits and limitations due to their specific molecular mechanisms. Consequently, the concept of conducting combined transplantation of two or more types of cells has emerged as a promising strategy.

There is a notable shift towards realizing potential therapeutic effects through the transplantation of a varied array of autologous or allogeneic stem/progenitor cells. This includes cell types such as embryonic and induced pluripotent stem cells, which have shown promising outcomes in preclinical studies involving animal models of neurological ailments. Consequently, these positive research findings are evolving into viable revenue opportunities for companies engaged in this specific sector.

Global Placental Stem Cell Therapy for Neurological Disorders Market Segmentation:

Global Placental Stem Cell Therapy for Neurological Disorders Market Segmentation: By Type

• Allogeneic Placental Stem Cell Therapy
• Autologous Placental Stem Cell Therapy

In 2022, the allogeneic placental stem cell therapy segment has asserted dominance within the market due to its distinctive ability to establish a new immune system in patients through successful integration of donor cells into the recipient's body. This methodology exhibits significant potential for treating a wide range of conditions, including neurological disorders, acute and chronic leukemia, Hodgkin's lymphoma, adrenoleukodystrophy, bone marrow failure syndromes, and more, through allogeneic stem cell transplants.

The increasing population of individuals grappling with cancer has spurred demand for treatments such as Omidubicel, an advanced cell therapy tailored for individuals with blood cancer. This demand is expected to propel growth within this specific segment. Contributing to the segment's expansion are factors such as cost-effectiveness and the broader accessibility of stem cell banking services.

Furthermore, the proactive shift of several cell therapy companies toward developing allogeneic cell therapy products adds momentum to the growth of this segment. With ongoing developments, the landscape of allogeneic stem cell therapy is poised for remarkable expansion, solidifying its position as a pivotal player in the medical treatment domain. Autologous Placental Stem Cell Therapy is the fastest-growing market during the forecast period.

Global Placental Stem Cell Therapy for Neurological Disorders Market Segmentation: By End-User

• Hospitals & Specialty Clinics
• Clinical Research Organizations
• Research Institutes & Academics

The clinical research organizations segment commands a dominant position in the market, boasting the highest market share in 2022. This prominence is attributable to the surge in research and development and the availability of dedicated funding for cell-focused investigations. The urgency for more advanced and effective treatments targeting autoimmune, cardiovascular, and neurological disorders is a driving force behind this trend. Additionally, the increasing demand for biologics and the expanding scope of research focused on discovering novel acquisition approaches with potential applications in developing personalized medicines collectively contribute to the robust expansion of the clinical research organizations sector. Hospitals and Specialty Clinics represent the fastest-growing market and are anticipated to hold a substantial market share during the forecast period.

Global Placental Stem Cell Therapy for Neurological Disorders Market Segmentation: By Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

In 2022, the North American region asserted its dominance with a 35% market share, establishing itself as the most influential region in the segment. This prominence is a result of the escalating allocation of research grants and both public and private investments committed to advancing safe and effective stem cell therapy products. Notably, the United States stands out as a focal point, experiencing a notable surge in clinical trials centered around placental stem cell applications, propelling overall growth in the region. Furthermore, the continuous evolution of placental stem cell therapy and the exceptional state of the healthcare sector synergistically contribute to the remarkable expansion of the market across North America.

The Asia-Pacific region emerges as the fastest-growing region and takes the lead as the primary driver of global growth. Projections indicate substantial expansion in the Asia-Pacific stem cell therapy sector over the upcoming decade. This trajectory is supported by the active participation of numerous public and private foundations dedicated to providing financial backing and support for initiatives in stem cell-based research. The expansive landscape of the stem cell therapy industry encompasses a diverse array of drugs derived from stem cells, addressing various ailments such as cancer, tissue regeneration, injuries, and accidents.

Key Players:

• Mesoblast Ltd.
• Pluristem Therapeutics
• ReNeuron Group
• AthersysInc.
• Cordlife India
• LifeCell International Pvt. Ltd
• Cryo-Cell International Inc.
• CBR Systems
• Cellularity Inc.
• Cynata

In December 2022, Celularity Inc., a clinical-stage biotech firm dedicated to the advancement of allogeneic cell therapies and biomaterial products sourced from the placenta, revealed its attainment of Halal Certification for its business models. This certification extends to its biomaterial products in the commercial stage, as well as its cellular therapeutic programs at both clinical and investigational stages.

In May 2022, ViaCyte, Inc. collaborated with SQZ Biotechnologies to jointly develop and bring to market microfluidic intracellular delivery technology for research-use-only (RUO) purposes. This partnership facilitates the exchange of innovative research in hematopoietic stem cell engineering between both entities involved in the market.